How does high PD-L1 expression affect treatment choices for advanced Non-Small Cell Lung Cancer?

For advanced non-small cell lung cancer (NSCLC), PD-L1 expression is a key biomarker that helps doctors decide whether to use immunotherapy. High PD-L1 (often defined as ≥50% tumor proportion score) generally means the tumor is more likely to respond to drugs that block the PD-1/PD-L1 pathway. However, treatment choices also depend on other factors like genetic mutations and overall health.

What the research says

A large real-world meta-analysis of over 17,500 patients with advanced NSCLC and PD-L1 ≥50% found that first-line pembrolizumab (an immunotherapy) led to an average overall survival of 21.0 months and a 5-year survival rate of 29% ⁸. This supports pembrolizumab as a standard first-line option for high PD-L1 tumors. Another real-world study of 237 patients with advanced NSCLC treated with immune checkpoint inhibitors reported a median progression-free survival of 11.3 months and an objective response rate of 55.7%, with PD-L1 expression being one factor among several that influenced outcomes ⁹.

However, high PD-L1 does not guarantee response, and other biomarkers matter. A case report describes a patient with both high PD-L1 (99%) and a MET exon 14 skipping mutation. Initial immunotherapy (tislelizumab) provided only 7 months of control, but switching to a MET inhibitor (savolitinib) led to significant tumor shrinkage, suggesting that driver mutations can override PD-L1 status ³. Similarly, for patients with EGFR mutations, targeted therapies like lazertinib plus amivantamab are preferred regardless of PD-L1 level ⁵.

Timing of immunotherapy may also matter. A meta-analysis of 29 studies found that early time-of-day administration of immune checkpoint inhibitors was associated with better overall survival in advanced solid tumors, including NSCLC ⁶. This suggests that when you receive treatment could influence outcomes, though this is not yet standard practice.

For potentially resectable NSCLC, neoadjuvant immunotherapy combined with chemotherapy is being studied. A meta-analysis of 34 studies reported high rates of major pathological response and complete resection, but PD-L1 expression was not the only predictor ⁴. In contrast, PET/CT metabolic parameters like ΔSUVmax% can help predict response after neoadjuvant therapy, but this is not directly about PD-L1 ¹.

What to ask your doctor

• What is my PD-L1 expression level, and how does it affect my treatment options?
• Should I be tested for other biomarkers like EGFR, ALK, or MET mutations before starting immunotherapy?
• If I have high PD-L1, is immunotherapy alone recommended, or should it be combined with chemotherapy?
• Does the time of day I receive immunotherapy matter for my outcomes?
• What are the possible side effects of immunotherapy, and how are they managed?